Remedium Lifecare Expands Globally with Singapore Subsidiary, Secures ₹182.7 Crore Export Contract

Remedium Lifecare Limited has taken significant steps to strengthen its global presence and transition into a full-spectrum pharmaceutical solutions provider. The company has recently announced several strategic initiatives aimed at driving long-term growth and expanding its international footprint.

Singapore Subsidiary Establishment

Remedium has established REMLIFE GLOBAL PTE. LTD., a wholly owned subsidiary in Singapore, to serve as its global commercial and capital markets interface. This move is expected to enhance the company's ability to tap into global investor ecosystems, streamline international operations, and deepen its reach across key markets.

Major Export Contract

In a significant development, Remedium secured a multi-year export contract worth ₹182.70 crore (USD 21.00 million) with a leading pharmaceutical distributor. This contract underscores the growing global credibility of Remedium's operations and highlights the company's successful transition from a trading-led model to a full-spectrum solutions provider.

Successful Rights Issue

The company recently completed a rights issue that received strong investor participation. The proceeds from this issue are being strategically deployed for:

• Research and Development (R&D) upgrades
• Contract Development and Manufacturing Organization (CDMO) infrastructure improvements
• Expansion into regulated international markets

This robust investor response demonstrates confidence in Remedium's business fundamentals and future potential.

Strategic Partnerships

Through its Singapore subsidiary, Remedium has partnered with Jia Yu Lifesciences PTE Ltd, a green chemistry platform focused on replacing animal-origin raw materials with scalable, sustainable bioprocesses. This collaboration is expected to strengthen Remedium's innovation-led sustainability efforts.

Infrastructure and Quality Enhancements

Remedium has invested in enhancing its quality control and testing infrastructure to support its growing CDMO client base. While these upgrades do not immediately expand manufacturing capacity, they significantly improve the company's analytical, formulation, and compliance capabilities.

Future Outlook

Adarsh Munjal, Whole Time Director of Remedium Lifecare Ltd, stated, "The incorporation of Remlife Global PTE Ltd in Singapore marked a pivotal milestone in our global strategy, enabling us to engage with international partners, raise capital more efficiently, and build long-term traction in high-opportunity markets."

With a maturing global order book, diversified sourcing across India, Eastern Europe, and Southeast Asia, and embedded inventory buffers, Remedium is positioning itself to navigate geopolitical uncertainties while scaling the delivery of high-value products.

As the company continues its transformation, it aims to become a differentiated and trusted global pharma partner, focusing on complex pharma products, regulatory-first strategies, cost-efficient CDMO services, and a strong sustainability focus.